Investor Presentaiton
DS-5670 Current development status
Development of COVID-19 vaccine progressed
FY2021
FY2022
H1
H2
H1
Ph1/2 study
Ph1/2/3 booster vaccination
Planning
Ph3 study
in Japan
(JP)
Dose setting
Ph2
Development of initial vaccination
=
Dose setting Ph2 study
●
•
Results presented no significant safety
concerns.
The neutralizing antibody titers 14 days
after the 2nd shot of DS-5670 have
demonstrated adequate immunity.
- Planning to start Ph3 study in Japan in
FY2022 H1
Study design
.
Subjects: COVID-19 unvaccinated Japanese
healthy adults
• Randomized, non-controlled, parallel-
group comparison study (30μg and 60µg)
• Investigate safety, immunogenicity (anti-
SARS-CoV-2 neutralizing activity of RBD
IgG in blood, antibody titer) and PK
H2
Daiichi-Sankyo
33View entire presentation